GSK’s Dr Anne Phillips moves to Novo Nordisk
pharmafile | January 4, 2011 | Appointment | Research and Development, Sales and Marketing | Dr Anne Phillips, Novo Nordisk, apppointment, research and development, sales and marketing
Novo Nordisk has appointed Dr Anne Phillips as vice president for clinical, medical and regulatory affairs for North America.
She moves to the company from GlaxoSmithKline, where she spent 12 years working within that firm’s research and development organisation.
In her new role Anne will lead Novo’s North American clinical development and medical affairs activities across its diabetes and biopharmaceutical franchises, as well as its regulatory affairs and medical operations.
She will serve as a member of the US executive team and report directly to Jerzy Gruhn, president of Novo’s US affiliate.
He said: “We’re pleased to welcome Dr Phillips and her significant clinical development and regulatory experience to the leadership team here at Novo Nordisk.
“Our development activity is moving at an incredible pace, and she brings the right mix of global and regional perspective that will complement our efforts.”
Anne replaces Dr Per Falk, who has been promoted to senior vice president for Novo Nordisk’s Biopharmaceuticals Research Unit in Denmark.
Related Content
CHMP recommends Novo Nordisk’s Awiqli for diabetes treatment
Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for …
Almirall licenses Novo Nordisk’s anti-IL-21 monoclonal antibody for dermatology treatment
Almirall has announced that it has entered into an exclusive license agreement with Novo Nordisk …
Novo Nordisk shares positive results from COMBINE 3 phase 3a trial
Novo Nordisk has shared topline results from the COMBINE 3 phase 3a trial of once-weeklly …